메뉴 건너뛰기




Volumn 9, Issue 2, 2014, Pages

Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: Retrospective testing of specimens from the EURTAC trial

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

EID: 84896075412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089518     Document Type: Article
Times cited : (31)

References (39)
  • 1
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3    Haanen, J.B.4    Ascierto, P.5
  • 2
    • 84869462031 scopus 로고    scopus 로고
    • Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology
    • Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ (2012) Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17: 1351-1375.
    • (2012) Oncologist , vol.17 , pp. 1351-1375
    • Ou, S.H.1    Bartlett, C.H.2    Mino-Kenudson, M.3    Cui, J.4    Iafrate, A.J.5
  • 3
    • 84873974299 scopus 로고    scopus 로고
    • Crizotinib: A new treatment option for ALK-positive non-small cell lung cancer
    • O'Bryant CL, Wenger SD, Kim M, Thompson LA (2013) Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Annals Pharmacotherapy 47: 189-197.
    • (2013) Annals Pharmacotherapy , vol.47 , pp. 189-197
    • O'Bryant, C.L.1    Wenger, S.D.2    Kim, M.3    Thompson, L.A.4
  • 4
    • 84870318934 scopus 로고    scopus 로고
    • A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK
    • Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, et al. (2012) A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 7: e36-38.
    • (2012) J Thorac Oncol , vol.7
    • Sun, J.M.1    Choi, Y.L.2    Won, J.K.3    Hirsch, F.R.4    Ahn, J.S.5
  • 6
    • 84879666728 scopus 로고    scopus 로고
    • Validation of Companion Diagnostic for Detection of Mutations in Codons 12 and 13 of the KRAS Gene in Patients with Metastatic Colorectal Cancer: Analysis of the NCIC CTG CO.17 Trial
    • Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, et al. (2012) Validation of Companion Diagnostic for Detection of Mutations in Codons 12 and 13 of the KRAS Gene in Patients with Metastatic Colorectal Cancer: Analysis of the NCIC CTG CO.17 Trial. Arch Pathol Lab Med 137: 820-827.
    • (2012) Arch Pathol Lab Med , vol.137 , pp. 820-827
    • Harbison, C.T.1    Horak, C.E.2    Ledeine, J.M.3    Mukhopadhyay, P.4    Malone, D.P.5
  • 7
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
    • (2010) N Engl J Med , vol.362 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3    Sugawara, S.4    Oizumi, S.5
  • 8
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947- 957.
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3    Yang, C.H.4    Chu, D.T.5
  • 9
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
    • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3    Feng, J.4    Liu, X.Q.5
  • 10
    • 80052972204 scopus 로고    scopus 로고
    • A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
    • Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, et al. (2011) A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 29: 3567-3573.
    • (2011) J Clin Oncol , vol.29 , pp. 3567-3573
    • Hirsch, F.R.1    Kabbinavar, F.2    Eisen, T.3    Martins, R.4    Schnell, F.M.5
  • 11
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
    • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3    Vergnenegre, A.4    Massuti, B.5
  • 12
    • 45149084723 scopus 로고    scopus 로고
    • First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, et al. (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-2449.
    • (2008) J Clin Oncol , vol.26 , pp. 2442-2449
    • Sequist, L.V.1    Martins, R.G.2    Spigel, D.3    Grunberg, S.M.4    Spira, A.5
  • 13
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
    • (2010) Lancet Oncol , vol.11 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3    Negoro, S.4    Okamoto, I.5
  • 14
    • 33750302365 scopus 로고    scopus 로고
    • Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
    • DOI 10.1158/1078-0432.CCR-06-0714
    • Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769. (Pubitemid 44629607)
    • (2006) Clinical Cancer Research , vol.12 , Issue.19 , pp. 5764-5769
    • Kosaka, T.1    Yatabe, Y.2    Endoh, H.3    Yoshida, K.4    Hida, T.5    Tsuboi, M.6    Tada, H.7    Kuwano, H.8    Mitsudomi, T.9
  • 18
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    • Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS 2: 225-235.
    • (2005) PLoS , vol.2 , pp. 225-235
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3    Riely, G.J.4    Somwar, R.5
  • 19
    • 33846187218 scopus 로고    scopus 로고
    • Update on epidermal growth factor receptor mutations in non-small cell lung cancer
    • DOI 10.1158/1078-0432.CCR-06-0658
    • Riely GJ, Politi KA, Miller VA, Pao W (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-7241. (Pubitemid 46095394)
    • (2006) Clinical Cancer Research , vol.12 , Issue.24 , pp. 7232-7241
    • Riely, G.J.1    Politi, K.A.2    Miller, V.A.3    Pao, W.4
  • 21
    • 84860709024 scopus 로고    scopus 로고
    • Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
    • Garrido P, de Castro J, Concha A, Felip E, Isla D, et al. (2012) Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin & Transl Oncol 14: 338-349.
    • (2012) Clin & Transl Oncol , vol.14 , pp. 338-349
    • Garrido, P.1    De Castro, J.2    Concha, A.3    Felip, E.4    Isla, D.5
  • 22
    • 79957492069 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
    • Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, et al. (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127.
    • (2011) J Clin Oncol , vol.29 , pp. 2121-2127
    • Keedy, V.L.1    Temin, S.2    Somerfield, M.R.3    Beasley, M.B.4    Johnson, D.H.5
  • 24
    • 84879290901 scopus 로고    scopus 로고
    • Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 15: 415-453.
    • (2013) J Mol Diagn , vol.15 , pp. 415-453
    • Lindeman, N.I.1    Cagle, P.T.2    Beasley, M.B.3    Chitale, D.A.4    Dacic, S.5
  • 26
    • 69949186250 scopus 로고    scopus 로고
    • Screening for epidermal growth factor receptor mutations in lung cancer
    • Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-969.
    • (2009) N Engl J Med , vol.361 , pp. 958-969
    • Rosell, R.1    Moran, T.2    Queralt, C.3    Porta, R.4    Cardenal, F.5
  • 32
    • 77951725120 scopus 로고    scopus 로고
    • A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma
    • Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, et al. (2010) A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 12: 292-299.
    • (2010) J Mol Diagn , vol.12 , pp. 292-299
    • Angulo, B.1    Garcia-Garcia, E.2    Martinez, R.3    Suarez-Gauthier, A.4    Conde, E.5
  • 33
    • 34249789581 scopus 로고    scopus 로고
    • EGFR and K-ras mutation analysis in non-small cell lung cancer: Comparison of paraffin embedded versus frozen specimens
    • Gallegos Ruiz MI, Floor K, Rijmen F, Grunberg K, Rodriguez JA, et al. (2007) EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 29: 257-264. (Pubitemid 46855706)
    • (2007) Cellular Oncology , vol.29 , Issue.3 , pp. 257-264
    • Gallegos, R.M.I.1    Floor, K.2    Rijmen, F.3    Grunberg, K.4    Rodriguez, J.A.5    Giaccone, G.6
  • 35
    • 84867555830 scopus 로고    scopus 로고
    • Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed Paraffin-Embedded Tissue Specimens of Malignant Melanoma
    • Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, et al. (2012) Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed Paraffin-Embedded Tissue Specimens of Malignant Melanoma. Arch Pathol Lab Med 136: 1385-1391.
    • (2012) Arch Pathol Lab Med , vol.136 , pp. 1385-1391
    • Anderson, S.1    Bloom, K.J.2    Vallera, D.U.3    Rueschoff, J.4    Meldrum, C.5
  • 37
    • 70449377167 scopus 로고    scopus 로고
    • Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics
    • Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, et al. (2009) Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 4: e7746.
    • (2009) PLoS One , vol.4
    • Kotoula, V.1    Charalambous, E.2    Biesmans, B.3    Malousi, A.4    Vrettou, E.5
  • 38
    • 79958141524 scopus 로고    scopus 로고
    • Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories
    • Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, et al. (2011) Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories. J Thorac Oncol 6: 1006-1015.
    • (2011) J Thorac Oncol , vol.6 , pp. 1006-1015
    • Beau-Faller, M.1    Degeorges, A.2    Rolland, E.3    Mounawar, M.4    Antoine, M.5
  • 39
    • 79952698311 scopus 로고    scopus 로고
    • External quality assessment for KRAS testing is needed: Setup of a European program and report of the first joined regional quality assessment rounds
    • Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, et al. (2011) External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 16: 467-478.
    • (2011) Oncologist , vol.16 , pp. 467-478
    • Bellon, E.1    Ligtenberg, M.J.2    Tejpar, S.3    Cox, K.4    De Hertogh, G.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.